Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 201 to 225 of 797

TitleReference numberPublishedLast updated
Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitisTA825
Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal)TA826
Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal)TA822
Dexamethasone intravitreal implant for treating diabetic macular oedemaTA824
Brolucizumab for treating diabetic macular oedemaTA820
Avalglucosidase alfa for treating Pompe diseaseTA821
Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapiesTA819
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesotheliomaTA818
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDsTA815
Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancerTA816
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrenceTA817
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancerTA812
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitorsTA813
Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitisTA814
Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal)TA811
Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney diseaseTA809
Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrenceTA810
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDsTA803
Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglyceridesTA805
Belimumab for treating lupus nephritis (terminated appraisal)TA806
Roxadustat for treating symptomatic anaemia in chronic kidney diseaseTA807
Fenfluramine for treating seizures associated with Dravet syndromeTA808
Teduglutide for treating short bowel syndromeTA804
Faricimab for treating diabetic macular oedemaTA799
Faricimab for treating wet age-related macular degenerationTA800

Results per page

  1. 10
  2. 25
  3. 50
  4. All